-
In this issue: Anticholinergic drugs for COPD; pioglitazone for diabetes prevention; insulin degludec in Phase 3 trials; and FDA Actions.
-
-
Since its introduction in 2009, use of the non-latex FC2 Female Condom (Women's Health Co., Chicago) has grown.
-
What is your facility's policy on providing multiple pill packs? Results of a new study might make you rethink your strategy.
-
A ruptured ectopic pregnancy is the leading cause of maternal mortality in the first trimester and accounts for 10 to 15% of all maternal deaths.
-
After two pretreatment cycles, 196 patients with menorrhagia were randomized to tranexamic acid or placebo.
-
Recent investigation into the molecular pathogenesis of epithelial ovarian cancer has implicated two dominant phenotypes.
-
When the Ortho Evra transdermal contraceptive (Ortho Women's Health & Urology, Raritan, NJ) was introduced in 2002, use of the patch caught on quickly with young women.
-
You have just reviewed instructions on proper oral contraceptive (OC) use with your patient, a 22-year-old mother of three.
-
[Editor's note: This story discusses off-label use of the antidepressant medication escitalopram (Lexapro, Forest Laboratories, New York City).]
